HC Wainwright Analysts Increase Earnings Estimates for ROIV

Roivant Sciences Ltd. (NASDAQ:ROIV) – Stock analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Roivant Sciences in a research note issued to investors on Tuesday, February 10th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($1.55) per share for the year, up from their previous forecast of ($1.61). HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Roivant Sciences’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Roivant Sciences’ Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.79) EPS.

ROIV has been the topic of several other reports. Citigroup boosted their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Leerink Partners increased their target price on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research note on Saturday, February 7th. Finally, The Goldman Sachs Group upped their price objective on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average price target of $28.69.

Roivant Sciences Price Performance

ROIV opened at $26.75 on Friday. The company’s 50 day simple moving average is $22.60 and its two-hundred day simple moving average is $18.20. Roivant Sciences has a 1-year low of $8.73 and a 1-year high of $27.94. The firm has a market capitalization of $18.60 billion, a price-to-earnings ratio of -22.86 and a beta of 1.22.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 1,018,995 shares of the firm’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total value of $22,122,381.45. Following the completion of the sale, the insider owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. This trade represents a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total transaction of $26,299,000.00. Following the sale, the director owned 18,047,727 shares of the company’s stock, valued at approximately $365,105,517.21. The trade was a 6.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 11,156,880 shares of company stock worth $244,463,758. 10.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds have recently added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. lifted its holdings in shares of Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares during the last quarter. KLP Kapitalforvaltning AS lifted its stake in Roivant Sciences by 6.6% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 76,100 shares of the company’s stock valued at $858,000 after buying an additional 4,700 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Roivant Sciences by 28.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 43,612 shares of the company’s stock valued at $492,000 after buying an additional 9,548 shares during the last quarter. Finally, CWM LLC increased its position in Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after buying an additional 920 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.